D Cary Nicole L Lukovsky-Akhsanov Nadia F Gallardo-Romero Cassandra M Tansey Sharon D Ostergaard Willie D Taylor Jr Clint N Morgan Nathaniel Powell George W Lathrop And Christina L Hutson C.
In this study, we evaluated the pharmacokinetic profiles of meloxicam and sustained-release (SR) buprenorphine in prairiedogs. The 4 treatment groups were: low-dose meloxicam (0.2 mg/kg SC), high-dose meloxicam (4 mg/kg SC), low-dosebuprenorphine SR (0.9 mg/kg SC), and high-dose buprenorphine SR (1.2 mg/kg SC). The highest plasma concentrationsoccurred within 4 h of administration for both meloxicam treatment groups. The therapeutic range of meloxicam in prairiedogs is currently unknown. However, as compared with the therapeutic range documented in other species (0.39 – 0.91 μg/mL),the mean plasma concentration of meloxicam fell below the minimal therapeutic range prior to 24 h in the low-dose groupbut remained above therapeutic levels for more than 72 h in the high-dose group. These findings suggest that the currentmeloxicam dosing guidelines may be subtherapeutic for prairie dogs. The highest mean plasma concentration for buprenorphineSR occurred at the 24-h time point (0.0098 μg/mL) in the low-dose group and at the 8-h time point (0.015 μg/mL) forthe high-dose group. Both dosages of buprenorphine SR maintained likely plasma therapeutic levels (0.001 μg/mL, basedon previous rodent studies) beyond 72 h. Given the small scale of the study and sample size, statistical analysis was not performed. The only adverse reactions in this study were mild erythematous reactions at injection sites for buprenorphine SR.